Maura, Francesco http://orcid.org/0000-0002-5017-1620
Boyle, Eileen M.
Coffey, David
Maclachlan, Kylee http://orcid.org/0000-0001-7873-4854
Gagler, Dylan
Diamond, Benjamin http://orcid.org/0000-0002-8638-9365
Ghamlouch, Hussein
Blaney, Patrick http://orcid.org/0000-0002-9319-8866
Ziccheddu, Bachisio
Cirrincione, Anthony
Chojnacka, Monika http://orcid.org/0000-0001-7176-6108
Wang, Yubao
Siegel, Ariel
Hoffman, James E.
Kazandjian, Dickran http://orcid.org/0000-0002-6593-0917
Hassoun, Hani
Guzman, Emily
Mailankody, Sham http://orcid.org/0000-0002-2815-9561
Shah, Urvi A. http://orcid.org/0000-0001-8419-1091
Tan, Carlyn http://orcid.org/0000-0001-7922-2594
Hultcrantz, Malin http://orcid.org/0000-0002-9045-6495
Scordo, Michael
Shah, Gunjan L.
Landau, Heather
Chung, David J.
Giralt, Sergio
Zhang, Yanming
Arbini, Arnaldo
Gao, Qi
Roshal, Mikhail
Dogan, Ahmet http://orcid.org/0000-0001-6576-5256
Lesokhin, Alexander M.
Davies, Faith E.
Usmani, Saad Z.
Korde, Neha
Morgan, Gareth J. http://orcid.org/0000-0002-4271-6360
Landgren, Ola http://orcid.org/0000-0001-6485-4839
Funding for this research was provided by:
Leukemia and Lymphoma Society (6020-20)
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (P30 CA 240139)
Article History
Received: 3 November 2022
Accepted: 20 September 2023
First Online: 9 November 2023
Competing interests
: O.L. has received research funding from the National Institutes of Health (NIH), NCI, U.S. Food and Drug Administration, MMRF, International Myeloma Foundation, Leukemia and Lymphoma Society, Paula and Rodger Riney Myeloma Foundation, Tow Foundation, Myeloma Solutions Fund, Perelman Family Foundation, Rising Tide Foundation, Amgen, Celgene, Janssen, Takeda, Glenmark, Pfizer, Seattle Genetics and Karyopharm; has received honoraria from and/or served on advisory boards for Adaptive, Amgen, Binding Site, BMS, Celgene, Cellectis, Glenmark, Janssen, Juno and Pfizer; and serves on independent data monitoring committees for clinical trials lead by Takeda, Merck, Janssen and Theradex. G.J.M. has received funding from the NIH, NCI, MMRF, Leukemia and Lymphoma Society, Perelman Family Foundation, Amgen, Celgene, Janssen and Takeda; has received honoraria from and/or served on advisory boards for Adaptive, Amgen, BMS, Celgene and Janssen; and serves on independent data monitoring committees for clinical trials lead by Takeda, Karyopharm and Sanofi. M.S. has received clinical trial research support to the institution from Angiocrine Bioscience, Inc., Omeros Corporation and Amgen, Inc.; has provided consultancy services to Omeros Corporation, Angiocrine Bioscience, Inc. (past) and McKinsey & Company (past); has served on an ad hoc advisory board for Kite – A Gilead Company (past); and has received honoraria for CME activity from i3Health (past), Medscape, LLC. (past) and CancerNetwork. G.S. has received research funding to the institution from Janssen, Amgen, BMS, and Beyond Spring. DSMB for Arcellx. S.G. receives research funding from Miltenyi Biotec, Takeda Pharmaceutical Co., Celgene Corp., Amgen Inc., Sanofi, Johnson and Johnson, Inc. and Actinium Pharmaceuticals, Inc. and is on advisory boards for Kite Pharmaceuticals, Inc., Celgene Corp., Sanofi, Novartis, Johnson and Johnson, Inc., Amgen Inc., Takeda Pharmaceutical Co., Jazz Pharmaceuticals, Inc. and Actinium Pharmaceuticals, Inc. U.A.S. reports research funding support from Celgene/BMS and Janssen to the institution and nonfinancial research support; and personal fees from ACCC, MashUp MD, Janssen Biotech, Sanofi, BMS, MJH LifeSciences, Intellisphere, Phillips Gilmore Oncology Communications, i3 Health and RedMedEd outside the submitted work. S.U. has received research funding from Abbvie, Amgen, Array Biopharma, BMS, Celgene, Gilead, GSK, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX and Takeda; and has had advisory and/or consulting roles with Abbvie, Amgen, BMS, Celgene, EdoPharma, Genentech, Gilead, GSK, Janssen, K36 Therapeutics, Moderna, Novartis, Oncopeptides, Sanofi, Seattle Genetics, SecuraBio, SkylineDX, Takeda and TeneoBio. A.D. has served as a consultant for Incyte, EUSA Pharma and Loxo and receives research support from Roche and Takeda. B.D. has received honoraria from and served on advisory boards for Janssen and Sanofi. The remaining authors declare no competing interests.